Seoulin Bioscience Co.Ltd (038070) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.007x

Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) has a cash flow conversion efficiency ratio of 0.007x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩631.76 Million ≈ $428.14K USD) by net assets (₩86.05 Billion ≈ $58.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 038070 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Seoulin Bioscience Co.Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Seoulin Bioscience Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Seoulin Bioscience Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Seoulin Bioscience Co.Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Black Iron Inc. TO:BKI	0.093x
Shaftesbury Capital PLC LSE:SHC	0.010x
Aztec Minerals Corp V:AZT	-0.013x
ANAX Metals Ltd AU:ANX	-0.076x
Softing AG XETRA:SYT	0.015x
Next Science Ltd AU:NXS	2.498x
Shanghai Lingyun Industries Development Co Ltd SHG:900957	-0.002x
Desert Gold Ventures Inc V:DAU	-1.378x

Annual Cash Flow Conversion Efficiency for Seoulin Bioscience Co.Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Seoulin Bioscience Co.Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Seoulin Bioscience Co.Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩86.05 Billion ≈ $58.32 Million	₩4.76 Billion ≈ $3.23 Million	0.055x	+200.62%
2024-12-31	₩83.89 Billion ≈ $56.85 Million	₩-4.61 Billion ≈ $-3.13 Million	-0.055x	-590.65%
2023-12-31	₩83.06 Billion ≈ $56.29 Million	₩930.57 Million ≈ $630.63K	0.011x	+121.55%
2022-12-31	₩83.79 Billion ≈ $56.78 Million	₩-4.36 Billion ≈ $-2.95 Million	-0.052x	-143.64%
2021-12-31	₩74.86 Billion ≈ $50.73 Million	₩8.92 Billion ≈ $6.04 Million	0.119x	+93.73%
2020-12-31	₩59.92 Billion ≈ $40.61 Million	₩3.68 Billion ≈ $2.50 Million	0.061x	-49.85%
2019-12-31	₩59.71 Billion ≈ $40.46 Million	₩7.32 Billion ≈ $4.96 Million	0.123x	+57.79%
2018-12-31	₩53.72 Billion ≈ $36.40 Million	₩4.17 Billion ≈ $2.83 Million	0.078x	+207.51%
2017-12-31	₩51.49 Billion ≈ $34.90 Million	₩1.30 Billion ≈ $881.84K	0.025x	-55.42%
2016-12-31	₩48.60 Billion ≈ $32.94 Million	₩2.76 Billion ≈ $1.87 Million	0.057x	-37.62%
2015-12-31	₩45.30 Billion ≈ $30.70 Million	₩4.12 Billion ≈ $2.79 Million	0.091x	+43.12%
2014-12-31	₩43.14 Billion ≈ $29.24 Million	₩2.74 Billion ≈ $1.86 Million	0.063x	-46.57%
2013-12-31	₩41.57 Billion ≈ $28.17 Million	₩4.94 Billion ≈ $3.35 Million	0.119x	--

About Seoulin Bioscience Co.Ltd

KQ:038070 Korea Biotechnology

Market Cap

$30.03 Million

₩44.31 Billion KRW

Market Cap Rank

#23814 Global

#1629 in Korea

Share Price

₩5020.00

Change (1 day)

-3.09%

52-Week Range

₩4820.00 - ₩7990.00

All Time High

₩36786.63